METOZOLV ODT

Compare METOZOLV ODT  to:
Compare
Compare

Generic Name for METOZOLV ODT

Metoclopramide (as HCl) 5mg, 10mg; orally-disintegrating tabs; mint flavored.

Legal Classification:

Rx

Pharmacological Class for METOZOLV ODT

Prokinetic.

Manufacturer of METOZOLV ODT

Salix Pharmaceuticals, Inc.

Indications for METOZOLV ODT

Short-term (4–12 weeks) therapy for symptomatic refractory GERD.

Adult dose for METOZOLV ODT

Allow tablet to dissolve on tongue. 10–15mg 4 times daily 30 minutes before meals and at bedtime. Intermittent symptoms: up to 20mg prior to provoking situation; max 12 weeks per therapeutic course. Renal impairment: reduce dose.

Children's dosing for METOZOLV ODT

Not recommended.

Contraindications for METOZOLV ODT

When stimulation of GI motility may be dangerous (eg, obstruction, perforation, or hemorrhage). Pheochromocytoma. Epilepsy. Concomitant drugs which may cause extrapyramidal reactions (eg, antidepressants, antipsychotics, neuroleptics).

Warnings/Precautions for METOZOLV ODT

Discontinue if signs/symptoms of tardive dyskinesia develop; risk increases with duration of treatment and total cumulative dose. Parkinsonism. History of depression. Hypertension. CHF. Arrhythmia. Elderly. Pregnancy (Cat.B). Nursing mothers.

Interactions for METOZOLV ODT

Hypertensive crisis with MAOIs. Additive sedation with alcohol, other CNS depressants. Antagonized by anticholinergics and narcotics. Monitor insulin use; may diminish gastric and accelerate intestinal absorption of drugs or food.

Adverse Reactions for METOZOLV ODT

Headache, nausea, vomiting, fatigue, somnolence, dizziness, extrapyramidal effects, parkinsonism, tardive dyskinesia, neuroleptic malignant syndrome, hypertension.

How is METOZOLV ODT supplied?

Tabs—10 x 10 (blister packs)

Related Disease:

GERD {GERD}

Related Resources

Phase 2 study of TZP-102 for diabetic gastroparesis

June 29, 2010

Tranzyme Pharma announced positive results from its Phase 2 study of TZP-102 for the treatment of gastroparesis in patients with diabetes mellitus (DM).

NDA submitted for Xifaxan for treatment of non-constipation irritable bowel syndrome

June 08, 2010

Salix Pharmaceuticals announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Xifaxan (rifaximin 550 mg tablets) for the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS) and IBS-related bloating.

FDA accepts NDA for Duexa for ulcer risk reduction in arthritis patients

May 26, 2010

Horizon Pharma announced that its New Drug Application (NDA) for Duexa was accepted by the FDA for the reduction of the risk of development of upper gastrointestinal ulcers in patients with arthritis and pain.

Proton pump inhibitors (PPIs) class labeling change to include fracture risk

May 26, 2010

The FDA has notified healthcare professionals and patients of labeling changes for prescription and over-the-counter (OTC) proton pump inhibitors (PPIs) to include new safety information about a possible increased risk of fractures with the use of these medications.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions